{"entity":{"id":"juan-valle","kind":"person","name":"Juan W. Valle","aka":[],"tldr":"Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1.","summary":"Juan Valle was chief investigator of ABC-02, the UK trial that established gemcitabine plus cisplatin as first-line therapy for advanced biliary tract cancer, and a lead investigator of TOPAZ-1, which added durvalumab to that backbone. He has led the ABC series of biliary trials and international guidelines on cholangiocarcinoma. He now leads research strategy at the Cholangiocarcinoma Foundation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valle%20JW%5BAuthor%5D%20biliary"}],"tags":["biliary","chemotherapy","trialist"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab"],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":["abc-02","topaz-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief Medical Officer, Cholangiocarcinoma Foundation; Honorary Professor of Medical Oncology, University of Manchester and The Christie","institutionId":"the-christie","specialisms":["Biliary tract cancer","Cholangiocarcinoma","Chemotherapy and immunotherapy","Rare GI cancers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Valle%20JW%5BAuthor%5D%20biliary"}],"papers":[{"title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0908721"},{"title":"Biliary tract cancer","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)00153-7"}],"orcid":"0000-0002-1999-0863"},"route":"/people/juan-valle/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"institution":[{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"trial":[{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/"},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/"}],"paper":[{"id":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/"},{"id":"paper-bsg-cholangiocarcinoma-guideline-gut-2023","kind":"paper","name":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","route":"/key-papers/paper-bsg-cholangiocarcinoma-guideline-gut-2023/"},{"id":"paper-topaz-1-three-year-survival-j-hepatol-2025","kind":"paper","name":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","route":"/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/"},{"id":"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017","kind":"paper","name":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","route":"/key-papers/paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017/"},{"id":"paper-abc-06-folfox-second-line-lancet-oncol-2021","kind":"paper","name":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","route":"/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/"}],"roadmap":[{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"}]}}